Scroll down to the pharmaceutical revenue results and the 'infectious other' line which would correspond to incivo sales which totaled 301 million for the quarter. I estimate that two thirds of that were Incivo sales which would mean approximately $50 million in royalties to VRTX from JNJ in the first quarter this year assuming the 'mid twenty per cent' of total sales licensing agreement stated in the past with JNJ.
I have to lower my estimate on first quarter Incivo sales royalties to be paid to VRTX by JNJ to $33 million to be paid to VRTX for first quarter sales based on discussion below from the Q&A at the JNJ first qtr CC yesterday:
"I think your comment about INCIVO, the math is pretty good there. They contributed about 5% of the international growth so that gets you about the number, that $130 million number. So we're pleased with the first results on INCIVO as well. And Louise, you have other points to add to that?
Yes. So the question on the countries where it's launched, it's Germany, France, the Alpine countries, Nordics, Iberia, U.K. and Israel. And then the pricing discussions, they're still ongoing, but it's in the range of about EUR 25,000 per course."
There is some detail in the last half of the press release. International infectious disease sales are broken down into four categories - 3 categories by product name and a fourth labeled other. Incivo appears to be included in the other category.
The Other Infectious Disease category grew by a total of $177 million for the first quarter of 2012 versus first quarter 2011. So the maximum that Incivo sales could have been is $177 million.